曲美他嗪治疗冠心病心力衰竭的疗效分析被引量：3

导出

摘要目的:探究曲美他嗪治疗冠心病心力衰竭的临床疗效。方法:对照组给予常规治疗,观察组在此基础上给予曲美他嗪治疗,观察比较2组临床疗效。结果:治疗12个月后,观察组总有效率为93.02%,明显高于对照组的83.72%;治疗6个月和12个月,2组比较发现,观察组LVEF、LVESVI、6min步行距离均明显优于对照组,且复发再次住院人次少于对照组。结论:曲美他嗪治疗冠心病心力衰竭临床疗效确切,且可在不影响血流动力学基础上,有效改善心功能及心肌缺血,进一步保障患者生命质量,值得临床应用和推广。

作者张亚静顾旭吕静静丁志欣李建杰

机构地区郑州市中医院心病科

出处《中国伤残医学》 2014年第8期117-118,共2页 Chinese Journal of Trauma and Disability Medicine

关键词曲美他嗪冠心病心力衰竭疗效分析

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1张玉芝.曲美他嗪对冠心病心力衰竭患者运动耐量的影响[J].山东医药,2009,49(16):103-103. 被引量：2
2陈韵岱,赵立坤,田峰,杜志民,江洪,魏盟.曲美他嗪对冠状动脉介入治疗患者的心脏保护作用[J].中华内科杂志,2010,49(6):473-476. 被引量：30
3支步胜,嵇成峰,沈柏兰.盐酸曲美他嗪对冠心病心力衰竭患者N-末端脑钠素前体及心功能的影响[J].江苏医药,2012,38(23):2900-2901. 被引量：7
4李寅健,许文平,张敏华,黄春霞,李贺.曲美他嗪对慢性心力衰竭患者的心肌保护作用[J].广东医学,2010,31(14):1872-1874. 被引量：13

二级参考文献27

1Schiano P,Gabriel Steg P.Measurement and prevention of myocardial injury during percutaneous coronary intervention.Heart,2007,93:656-657.
2Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
3Lavanchy N,Martin J,Rossi A.Anti-ischemic effects of trimetazidine:31P-NMR spectroscopy in the isolated rat heart.Arch Int Pharmacodyn Ther,1987,286:97-110.
4Renaud JF.Internal pH,Na +,and Ca2 + regulation by trimetazidine during cardiac cell acidosis.Cardiovasc Drugs Ther,1988,1:677-686.
5Cuamieri C,Muscari C.Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.Pharmacology,1993,46:324-331.
6Boucher FR,Hearse DJ,Opie LH.Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts.J Cardiovasc Pharmacol,1994,24:45-49.
7Belcher PR,Drake-Holland AJ,Hynd JW,et al.Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.Cardiovasc Drugs Ther,1993,7:149-157.
8Williams FM,Tanda K,Kus M,et al.Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits.J Cardiovasc Pharmacol,1993,22:828-833.
9Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
10Lopaschuk GD,Barr R,Thomas PD,et al.Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3-ketoacyl coenzyme a thiolase.Circ Res,2003,93:e33-37.